10940
Biochemistry 1999, 38, 10940-10948
Engineered Recombinant Factor VII Q217 Variants with Altered Inhibitor Specificities† Yu-Jia Chang,‡ Nobuko Hamaguchi,§ Shu-Chuan Chang,‡ Wolfram Ruf,| Ming-Ching Shen,‡ and Shu-Wha Lin*,‡ Graduate Institute of Medical Technology and Department of Laboratory of Medical Sciences, College of Medicine, National Taiwan UniVersity, Taiwan, ROC, Brandeis UniVersity, Rosenstiel Center, Waltham, Massachusetts 02454, and Department of Immunology, The Scripps Research Institute, La Jolla, California 92037 ReceiVed January 8, 1999; ReVised Manuscript ReceiVed June 7, 1999
ABSTRACT: Recombinant factor VII with residue 217 (chymotrypsinogen numbering system) converted to alanine (VIIQ217A), glutamic acid (VIIQ217E), or glycine (VIIQ217G) was characterized. In a prothrombin time assay, VIIQ217E demonstrated 100%, VIIQ217A 15%, and VIIQ217G
